Poll

Poll: How familiar are you on the approval process for biosimilar drugs in comparison to new drug applications to the FDA?

Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.

How familiar are you on the approval process for biosimilar drugs in comparison to new drug applications to the FDA?

Very familiar
Familiar
Slightly or somewhat familiar
Not familiar

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
© 2025 MJH Life Sciences

All rights reserved.